Psilocybin for Methamphetamine Addiction

Part of paid clinical trials in Shreveport, Louisiana.

Sponsor
Kevin Murnane
Study ID
NCT06899594
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Methamphetamine Use Disorder

Eligibility Criteria

Sex
ALL
Age
25 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin 25 mg — DRUG
    25 mg administered orally (capsules)

Study Details

The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.

Key Dates

Start date
Apr 4, 2025
Status verified
Mar 2025
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Psilocybin
    Participants will be administered 25mg of Psilocybin.

Primary Outcome Measure

Participant retention rate [ Time Frame: Screening, Visit #1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
LSU Health ShreveportShreveportLouisiana71103-

Find similar trials in Shreveport, LA

By research site
LSU Health Shreveport· Shreveport, LA

Related Studies